Success Metrics

Clinical Success Rate
87.0%

Based on 94 completed trials

Completion Rate
87%(94/108)
Active Trials
1(1%)
Results Posted
36%(34 trials)
Terminated
14(11%)

Phase Distribution

Ph not_applicable
18
15%
Ph phase_2
22
18%
Ph phase_3
30
25%
Ph phase_4
34
28%
Ph phase_1
14
11%

Phase Distribution

14

Early Stage

22

Mid Stage

64

Late Stage

Phase Distribution118 total trials
Phase 1Safety & dosage
14(11.9%)
Phase 2Efficacy & side effects
22(18.6%)
Phase 3Large-scale testing
30(25.4%)
Phase 4Post-market surveillance
34(28.8%)
N/ANon-phased studies
18(15.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.9%

94 of 112 finished

Non-Completion Rate

16.1%

18 ended early

Currently Active

1

trials recruiting

Total Trials

122

all time

Status Distribution
Active(1)
Completed(94)
Terminated(18)
Other(9)

Detailed Status

Completed94
Terminated14
unknown8
Withdrawn4
Recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
122
Active
1
Success Rate
87.0%
Most Advanced
Phase 4

Trials by Phase

Phase 114 (11.9%)
Phase 222 (18.6%)
Phase 330 (25.4%)
Phase 434 (28.8%)
N/A18 (15.3%)

Trials by Status

recruiting11%
completed9477%
suspended11%
terminated1411%
unknown87%
withdrawn43%

Recent Activity

Clinical Trials (122)

Showing 20 of 122 trialsScroll for more
NCT04114136Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Recruiting
NCT02694874Not Applicable

Rosiglitazone Adjunctive Therapy for Severe Malaria in Children

Completed
NCT00297063Phase 3

BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Completed
NCT01019356Not Applicable

Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

Completed
NCT00081328Phase 3

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)

Completed
NCT00265148Phase 2

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

Completed
NCT01287598Phase 1

BAY73-4506 Probe Substrate Study

Completed
NCT00481429

Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study

Withdrawn
NCT00285142Not Applicable

Effect of Rosiglitazone

Completed
NCT00427154Phase 3

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

Terminated
NCT00577590Not Applicable

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

Completed
NCT00679939Phase 4

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

Completed
NCT00194896Not Applicable

Preferred Treatment of Type 1.5 Diabetes

Completed
NCT00065065Phase 2

A Trial of Rosiglitazone for Ulcerative Colitis

Completed
NCT00370305Phase 2

11ß-HSD1 and Metabolic Syndrome

Completed
NCT00964106Phase 1

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Completed
NCT00279045Phase 3

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Completed
NCT00640224Phase 4

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

Completed
NCT03309319Not Applicable

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Unknown
NCT00044460Phase 4

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Completed

Drug Details

Intervention Type
DRUG
Total Trials
122